Anemia - Drug Pipeline Analysis and Market Forecasts to 2016
05/04/2010

The Anemia Market is Expected to Witness Marginal Decline Due to Rising Safety Concerns over ESA Therapies and Weak Late-Stage Pipeline

Online PR News – 04-May-2010 – – GlobalData valued the anemia market in 2009 at $10.4 billion, indicating a CAGR of 8.5% between 2001 and 2009. The main driver for the growth of the anemia market is the rapid utilization of Erythropoietin Stimulating Agents (ESAs) such as Aranesp (darbepoeitin alfa), Procrit (epoetin alfa), Epogen (epoetin alfa) and Neorecormon (epoetin beta). These therapies are biological in nature and the annual cost of anemia therapy with these drugs ranges between $3,000 and $8,000. The majority of these therapies were launched between 2001 and 2007 and as a result market growth was pronounced in that period. In 2007, safety concerns over the use of ESAs surfaced and this has led to a decline in the sales of the drugs. Since then, the growth in the anemia market has been declining. Between 2009 and 2016, the market is expected to decline further as there are no key promising therapies expected to enter the anemia market. Further, biosimilars of ESAs have already entered the European market and are expected to enter the US market between 2009 and 2016. This factor is also expected to restrain the growth of the market.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Anemia-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare

GlobalData evaluated the current competition in the anemia market as weak. Though iron deficiency anemia accounts for 40% of the total anemia population, none of the drugs indicated for iron deficiency anemia became a blockbuster. However, a majority of ESAs that are indicated for selected types of anemia are blockbusters and currently dominate the market. This shows that there is not strong competition between drugs in the anemia market. Further, the ESAs approved for anemia treatment were found to carry severe cardiovascular side effects and the FDA consequently issued guidelines about the safety of these therapies. These guidelines are expected to diminish the prescription volume of ESA therapies. Hence, the current competition in the anemia market is estimated to be weak.

GlobalData analyzed the pipeline in anemia market and concluded that the pipeline is very weak. There are only 32 molecules in clinical development and approximately 80 clinical trials are being conducted on the 32 molecules. Phase III clinical development includes nine molecules and contributes to 28.1% of the anemia pipeline. Phase II clinical development includes 12 molecules and accounts for 37.5% of the anemia pipeline. The early stage development pipeline (the Phase I, preclinical and discovery stages) includes only 11 molecules.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Anemia-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare

GlobalData’s report, "Anemia - Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global anemia market. The report provides insight on the prevalent competitive landscape and the emerging players as well as the pipeline products within the global anemia sector. GlobalData valued the anemia market in 2009 at $10.4 billion. The main driver for the growth of the anemia market is the rapid utilization of Erythropoietin Stimulating Agents (ESAs) such as Aranesp (darbepoeitin alfa), Procrit (epoetin alfa), Epogen (epoetin alfa) and Neorecormon (epoetin beta). These therapies are biological in nature and the annual cost of anemia therapy with these drugs ranges between $3,000 and $8,000. GlobalData evaluated the current competition in the anemia market as weak. Though iron deficiency anemia accounts for 40% of the total anemia population, none of the drugs indicated for iron deficiency anemia became a blockbuster. However, the majority of the ESAs that are indicated for selected types of anemia are blockbusters and currently dominate the market.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Anemia-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare

Or visit our report store: http://www.globaldata.com/reportstore